Wyss Institute researchers outlined a concept for a non-invasive fetal oxygenation monitor using maternal blood extracellular vesicles (EVs). The approach, dubbed FEMOx, aims to quantify hypoxia-associated EV cargo as an alternative to fetal heart rate monitoring, which does not directly measure oxygen levels. The team described that EVs from hypoxia-stressed fetal cells can carry RNA or protein cargo reflecting hypoxic stress, enabling biomarker readouts in maternal samples. The proposal is positioned as a way to reduce uncertainty around fetal hypoxic distress and potentially lower unnecessary cesarean deliveries. The scientific premise aligns with EV biomarker development in other clinical contexts, but this report is framed as translational development rather than clinical validation. For obstetric care technology, the bottleneck will be demonstrating reliable clinical sensitivity/specificity across gestational ages and delivery scenarios, and proving that biomarker-guided decisions improve outcomes.